Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection.
Stevenson
W
W
Department of Surgery, University of Virginia Health Science Center, Charlottesville 22908.
Gaffey
M
M
Ishitani
M
M
McCullough
C
C
Dickson
R
R
Caldwell
S
S
Lobo
P
P
Pruett
T
T
D000998:Antiviral Agents / Q000627:therapeutic use* / Q000633:toxicity*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007773:Lactates / Q000097:blood; D016031:Liver Transplantation; D016032:Randomized Controlled Trials as Topic
D000998:Antiviral Agents; D007773:Lactates; D001086:Arabinofuranosyluracil; C043457:fialuridine